cataract surgery
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bilateral Cataract
Conditions
Bilateral Cataract
Trial Timeline
Nov 1, 2013 → Mar 1, 2016
NCT ID
NCT02734459About cataract surgery
cataract surgery is a phase 3 stage product being developed by GenZum Life Sciences for Bilateral Cataract. The current trial status is completed. This product is registered under clinical trial identifier NCT02734459. Target conditions include Bilateral Cataract.
What happened to similar drugs?
1 of 1 similar drugs in Bilateral Cataract were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02734459 | Phase 3 | Completed |
Competing Products
3 competing products in Bilateral Cataract
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 32 |
| Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7% | Ocular Therapeutix | Approved | 37 |
| ACT-774312 + Placebo | Idorsia | Phase 2 | 29 |